^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Ocrevus (ocrelizumab)

    i
    Other names: PRO 70769, R 1594, RG1594, rhuMab 2H7, PRO70769, OCR, RO4964913, PRO-70769, R1594, RO-4964913, RG 1594, RO 4964913, R-1594, RG-1594
    Associations

    News

    Trials
    Company:
    Biogen, Roche
    Drug class:
    CD20 inhibitor
    Related drugs:
    Associations

    News

    Trials
    6d
    OPA: Ocrelizumab for Psychosis by Autoimmunity (clinicaltrials.gov)
    P1/2, N=40, Recruiting, The Methodist Hospital Research Institute | Trial completion date: Oct 2025 --> Oct 2028 | Trial primary completion date: Jun 2025 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    Ocrevus (ocrelizumab)
    7d
    Operetta III: A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov)
    P2, N=25, Not yet recruiting, Hoffmann-La Roche
    New P2 trial
    |
    Ocrevus (ocrelizumab)
    8d
    Mintaka: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) (clinicaltrials.gov)
    P2, N=360, Recruiting, Hoffmann-La Roche
    Trial initiation date
    |
    Ocrevus (ocrelizumab)
    11d
    Ocular toxicity associated with anti-CD20 monoclonal antibodies: A pharmacovigilance analysis using the FAERS database. (PubMed, Mult Scler Relat Disord)
    Anti-CD20 antibodies require careful ocular monitoring, particularly in multiple sclerosis patients. The elevated blepharospasm risks with ofatumumab and dyschromatopsia with rituximab highlights potential CNS-and optic pathway-related effects that warrant further study to improve MS treatment safety.
    Journal • Adverse events
    |
    ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
    |
    Rituxan (rituximab) • Gazyva (obinutuzumab) • Briumvi (ublituximab-xiiy) • Ocrevus (ocrelizumab)
    11d
    OCREFINA: Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis (clinicaltrials.gov)
    P4, N=5, Enrolling by invitation, University of California, San Francisco | Recruiting --> Enrolling by invitation | Trial completion date: Dec 2025 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Jun 2027
    Enrollment status • Trial completion date • Trial primary completion date
    |
    Ocrevus (ocrelizumab)
    13d
    21-PP-23: LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB IN FRENCH PATIENTS WITH PROGRESSIVE MS: CONSONANCE EXTENSION STUDY (2024-516433-13-00)
    P2/3, N=89, Recruiting, Centre Hospitalier Universitaire De Nice | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Ocrevus (ocrelizumab)
    19d
    A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis (clinicaltrials.gov)
    P4, N=60, Recruiting, Hoffmann-La Roche
    New P4 trial
    |
    Ocrevus (ocrelizumab)
    23d
    Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis (clinicaltrials.gov)
    P3, N=126, Recruiting, Sandoz | N=87 --> 126
    Enrollment change
    |
    Ocrevus (ocrelizumab)
    29d
    ORATORIO-CP: Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS (clinicaltrials.gov)
    P=N/A, N=732, Completed, State University of New York at Buffalo | Active, not recruiting --> Completed
    Trial completion
    |
    Ocrevus (ocrelizumab)
    2ms
    Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. (clinicaltrials.gov)
    P3, N=360, Recruiting, Novartis Pharmaceuticals | Trial completion date: Dec 2031 --> Jun 2031 | Trial primary completion date: Jan 2030 --> Jul 2029
    Trial completion date • Trial primary completion date • Head-to-Head
    |
    Rhapsido (remibrutinib) • Ocrevus (ocrelizumab)
    2ms
    CN45320: A Study to Assess Bioequivalence of Two Subcutaneous Formulations of Ocrelizumab in Participants with Multiple Sclerosis (2024-517980-22-00)
    P1/2, N=86, Recruiting, F. Hoffmann-La Roche AG
    New P1/2 trial
    |
    Ocrevus (ocrelizumab)
    2ms
    BP46016: A study to compare different doses of RO7268489 with a placebo (as add-on therapy to ocrelizumab) in people with multiple sclerosis that has progressed (2025-521636-10-00)
    P1/2, N=220, Recruiting, F. Hoffmann-La Roche AG
    New P1/2 trial
    |
    Ocrevus (ocrelizumab)